Table 2.
Glycaemic targets for individuals with type 1 diabetes
| ADA (16) | CDA (17) | IDF (51) | NICE (UK) (18) | |
|---|---|---|---|---|
| HbA1c | < 7.0% | ≤ 7.0% | 6.2–7.5% | ≤ 6.5–7.5% |
| Fasting preprandial glucose, mg/dl (mmol/l) | 70–130 (3.9–7.2) | 72–126 (4.0–7.0) | 91–120 (5.1–6.5) | 72–144 (4.0–8.0) |
| Postprandial glucose, mg/dl (mmol/l) | < 180* (< 10.0) | 90–180† (5.0–10.0) | 136–160‡ (7.6–9.0) | < 180‡ (< 10.0) |
ADA, American Diabetes Association; CDA, Canadian Diabetes Association; IDF, International Diabetes Federation; NICE, National Institute for Health and Clinical Excellence.
The CDA guidelines note that HbA1c goals and strategies must be tailored to the individual with diabetes, with consideration given to individual risk factors.
ADA and CDA glycaemic targets are for type 1 and type 2 diabetes.
*
Peak postprandial capillary plasma glucose.
†
90–144 mg/dl (5.0–8.0 mmol/l) if HbA1c target not being met.
‡
Capillary postprandial glucose 1–2 h after meal.